ANVS: Total Utang marang Modal Annovis Bio

Logo perusahaan publik Annovis Bio (ANVS)

The price indicator on the Annovis Bio, Inc. (ANVS) chart demonstrates a total debt-to-equity ratio of 0.00. This trend reflects the liquidity requirements for conducting dementia drug trials and protecting intellectual property. Stable management aims to successfully complete current testing phases to justify shareholder confidence. Efficiency is accelerating through the implementation of AI algorithms and robotics to discover new neuroprotection formulas.

ANVS - Total Utang marang Modal Annovis Bio ing rentang 04.07.2022 - 31.10.2026

Rincian metrik lan analitis perusahaan Annovis Bio Corporation (ANVS)

- rega lan prakiraan konsensus rega:
Bagan rega Annovis Bio|ANVS - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Annovis Bio|ANVS - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Annovis Bio|ANVS - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku annovisbio.com|ANVS - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Annovis Bio, Inc.|ANVS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Annovis Bio, Inc.|ANVS - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Annovis Bio|ANVS - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Annovis Bio|Likuiditas cepet annovisbio.com
- statistik bathi lan rasio pasar:
ANVS - Penghasilan resik perusahaan
Analisis dhasar perusahaan:ANVS, Annovis Bio
Barang utama Annovis Bio Corporation

This indicator is calculated as the ratio of total liabilities to equity, determining the extent of the business's dependence on external borrowings relative to its own resources. For Annovis Bio, Inc. (ANVS), a low debt load is critically important, as the high scalability of intellectual property allows for the capitalization of formulas without the risk of forced asset sales, which is confirmed by an analysis of the changing ratio of financial borrowings to equity.

Perusahaan pesaing

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|HRMY (Harmony Biosciences) - Total Utang marang Modal|Total Utang marang Modal biohavenpharma.com|Utang marang Ekuitas Amylyx Pharmaceuticals, Inc. (AMLX)|Trevi Therapeutics Inc - Rasio Utang marang Ekuitas|Utang marang Ekuitas Praxis Medicines PRAX|AVXL: Rasio Utang marang Ekuitas|CBLL - Utang marang Ekuitas|Utang marang Modal Prothena Corporation PLC|ALEC (alector.com) - Rasio Total Utang marang Ekuitas|ANNX (Annexon Biosciences) - Utang marang Ekuitas|OMER (Omeros Corp) - Total Utang marang Modal|Neurogene Therapeutics (NGNE) - Koefisien Total Utang marang Modal|Utang marang Ekuitas AC Immune (ACIU)|Koefisien Total Utang marang Modal voyagertherapeutics.com|Neumora Therapeutics, Inc. - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SCLX|Tevogen Bio Holdings, Inc. - Total Utang marang Modal|ACOG: Utang marang Ekuitas|CGTX: Total Utang marang Modal|IKT - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cassava Sciences|Utang marang Modal Assertio Therapeutics ASRT|Rasio Total Utang marang Ekuitas COYA (Coya Therapeutics, Inc.)|VTGN (vistagen.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal OVID (Ovid Therapeutics)|Koefisien Total Utang marang Modal acumenpharm.com (ABOS)|CRVO - Utang marang Ekuitas|ATHE (Alterity Therapeutics) - Rasio Utang marang Ekuitas|CLNN: Total Utang marang Modal|Rasio Total Utang marang Ekuitas PepGen|Rasio Total Utang marang Ekuitas JUNS|relmada.com (RLMD) - Koefisien Total Utang marang Modal|Total Utang marang Modal GRCE|Total Utang marang Modal Firefly Neuroscience, Inc. (AIFF)|Utang marang Ekuitas Klotho Neurosciences KLTO|NRSN: Rasio Utang marang Ekuitas|RVPH: Rasio Total Utang marang Ekuitas|MTVA: Utang marang Ekuitas|NeurAxis (NRXS) - Utang marang Ekuitas|HSDT - Koefisien Total Utang marang Modal|Utang marang Ekuitas Passage Bio Inc.|Rasio Utang marang Ekuitas NEUP (Neuphoria)|Total Utang marang Modal NERV|ATHA - Utang marang Modal|Addex Therapeutics Ltd - Rasio Total Utang marang Ekuitas|Total Utang marang Modal Alzamend Neuro Inc. ALZN|CYCN - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi PTIX (Protagenic Therapeutics)|pasitheaclinics.com (KTTA) - Utang marang Ekuitas|Utang marang Modal Cortigent (CRGT)|ATXI (Avenue Therapeutics, Inc.) - Total Utang marang Modal|Total Utang marang Modal Brainstorm Cell Therapeutics Inc.|Utang marang Ekuitas Cara Therapeutics, Inc (CARA)|Chromocell - Rasio Utang marang Ekuitas|Utang marang Ekuitas Eliem Therapeutics Inc. ELYM|ITCI: Rasio Utang marang Ekuitas|LBPH - Utang marang Ekuitas|Utang marang Modal Marinus Pharmaceuticals Inc|NKGN (NKGen) - Rasio Total Utang marang Ekuitas|NRBO (NeuroBo Pharma) - Utang marang Ekuitas|SAGE (Sage Therapeutics, Inc.) - Total Utang marang Modal|synaptogen.com (SNPX) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Trevena (TRVN)|Koefisien Total Utang marang Modal vigilneuro.com|Anew Medical - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CERE